Charting a path toward combination therapy for Alzheimer’s disease

References

• Mattson MP. Pathways towards and away from Alzheimer’s disease. Nature 2004;430(7000):631-9
   PubMed Web of Science ®Google Scholar
• Jack CRJr, Albert M, Knopman DS, et al. Introduction to revised criteria for the diagnosis of Alzheimer’s disease: national Institute on Aging and the Alzheimer’s Association workgroup. Alzheimers Dement 2011;7(3):257-62
   PubMed Web of Science ®Google Scholar
• DeVita VTJr, Chu E. A history of cancer chemotherapy. Cancer Res 2008;68(21):8643-53
   PubMed Web of Science ®Google Scholar
• Baselga J. Herceptin alone or in combination with chemotherapy in the treatment of HER2-positive metastatic breast cancer: pivotal trials. Oncology 2001;61 Suppl 2:14-21
   PubMed Web of Science ®Google Scholar
• Henderson IC, Berry DA, Demetri GD, et al. Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003;21(6):976-83
   PubMed Web of Science ®Google Scholar
• Berry DA. Adaptive clinical trials: the promise and the caution. J Clin Oncol 2010;29(6):606-9
   PubMed Web of Science ®Google Scholar
• Barker AD, Sigman CC, Kelloff GJ, et al. I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin Pharmacol Ther 2009;86(1):97-100
   PubMed Web of Science ®Google Scholar
• Mangialasche F, Solomon A, Winblad B, et al. Alzheimer’s disease: clinical trials and drug development. Lancet Neurol 2010;9(7):702-16
   PubMed Web of Science ®Google Scholar
• Howard R, McShane R, Lindesay J, et al. Donepezil and memantine for moderate-to-severe Alzheimer’s disease. N Engl J Med 2012;366(10):893-903
   PubMed Web of Science ®Google Scholar
• Peters O, Lorenz D, Fesche A, et al. A combination of galantamine and memantine modifies cognitive function in subjects with amnestic MCI. J Nutr Health Aging 2012;16(6):544-8
   PubMed Web of Science ®Google Scholar
• Gauthier S, Molinuevo JL. Benefits of combined cholinesterase inhibitor and memantine treatment in moderate-severe Alzheimer’s disease. Alzheimers Dement 2013;9(3):326-31
   PubMed Web of Science ®Google Scholar
• Herrup K, Carrillo M, Schenk D, et al. Beyond amyloid: getting real about nonamyloid targets in Alzheimer’s disease. Alzheimers Dement 2013;9(4):452-8
   PubMed Web of Science ®Google Scholar
• Bohrmann B, Caruso A, Tanghe A, et al. Combination therapy with Gantenerumab and BACE inhibitor accelerates amyloid lowering: New paradigm for treatment of Alzheimer’s disease? The 11th International Conference on Alzheimer’s & Parkinson’s Diseases; Florence, Italy; 2013
   Google Scholar
• Food and Drug Administration. Guidance for industry: Codevelopment of two or more unmarketed investigational drugs for use in combination. 2010. Available from: www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM236669.pdf [Last accessed on 13/04/14]
   Google Scholar
• Woodcock J, Griffin JP, Behrman RE. Development of novel combination therapies. N Engl J Med 2011;364(11):985-7
   PubMed Web of Science ®Google Scholar
• Sperling RA, Jack CRJr, Aisen PS. Testing the right target and right drug at the right stage. Sci Transl Med 2011;3(111):111cm33
   PubMed Web of Science ®Google Scholar
• Teipel SJ, Sabri O, Grothe M, et al. Perspectives for multimodal neurochemical and imaging biomarkers in Alzheimer’s disease. J Alzheimers Dis 2013;33(Suppl 1):S329-47
   PubMedGoogle Scholar
• Hampel H, Frank R, Broich K, et al. Biomarkers for Alzheimer’s disease: academic, industry and regulatory perspectives. Nat Rev Drug Discov 2010;9(7):560-74
   PubMed Web of Science ®Google Scholar
• Morris JC, Selkoe DJ, Holtzman DM, et al. Emerging consensus for Alzheimer’s biomarkers in clinical trials. Neurobiol Aging 2011;32:S1-S66
   PubMedGoogle Scholar
• Jack CRJr, Knopman DS, Jagust WJ, et al. Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade. Lancet Neurol 2010;9(1):119-28
   PubMed Web of Science ®Google Scholar
• Jack CRJr, Vemuri P, Wiste HJ, et al. Evidence for ordering of Alzheimer disease biomarkers. Arch Neurol 2011;68(12):1526-35
   PubMedGoogle Scholar
• Jack CRJr, Vemuri P, Wiste HJ, et al. Shapes of the trajectories of 5 major biomarkers of Alzheimer disease. Arch Neurol 2012;69(7):856-67
   PubMedGoogle Scholar
• Jack CRJr, Wiste HJ, Vemuri P, et al. Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer’s disease. Brain 2010;133(11):3336-48
   PubMed Web of Science ®Google Scholar
• Bateman RJ, Xiong C, Benzinger TLS, et al. Clinical, cognitive, and biomarker changes in the Dominantly Inherited Alzheimer Network. N Engl J Med 2012;367(9):795-804
   PubMed Web of Science ®Google Scholar
• Snyder HM, Bain LJ, Egge R, Carrillo MC. Alzheimer’s disease public-private partnerships: a landscape of the global nonprofit community. Alzheimers Dement 2013;9(4):466-71
   PubMed Web of Science ®Google Scholar
• World Health Organization. Global Tuberculosis Report; Geneva, Switzerland; 2012
   Google Scholar
• Romero K, de Mars M, Frank D, et al. The Coalition Against Major Diseases: developing tools for an integrated drug development process for Alzheimer’s and Parkinson’s diseases. Clin Pharmacol Ther 2009;86(4):365-7
   PubMed Web of Science ®Google Scholar
• Stephenson D, Aviles E, Bain LJ, et al. Coalition Against Major Diseases: precompetitive collaboration and regulatory paths to accelerating drug development for neurodegenerative diseases. Therapeutic Innovation & Regulatory Science 2013;47(6):632-8
   PubMedGoogle Scholar
• Neville J, Kopko S, Broadbent S et al., for the Coalition Against Major Diseases, Development of a unified clinical trial database for Alzheimer’s disease, Alzheimer’s and Dementia, in press
   Google Scholar
• Worley S. After disappointments, Alzheimer’s researchers seek out new paths: biomarkers and combination therapies may lead to disease-modifying treatments, experts say. P T 2014;39(5):365-74
   PubMedGoogle Scholar